{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,26]],"date-time":"2026-10-26T21:28:31Z","timestamp":1793050111604,"version":"4.5.0"},"reference-count":75,"publisher":"American Medical Association (AMA)","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Netw Open"],"DOI":"10.1001\/jamanetworkopen.2019.0828","type":"journal-article","created":{"date-parts":[[2019,3,22]],"date-time":"2019-03-22T15:32:54Z","timestamp":1553268774000},"page":"e190828","source":"Crossref","is-referenced-by-count":190,"title":["Assessment of Reported Comparative Effectiveness and Safety of Atypical Antipsychotics in the Treatment of Behavioral and Psychological Symptoms of Dementia"],"prefix":"10.1001","volume":"2","author":[{"given":"Ismaeel","family":"Yunusa","sequence":"first","affiliation":[{"name":"School of Pharmacy, Massachusetts College of Pharmacy and Health Sciences, Boston"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adnan","family":"Alsumali","sequence":"additional","affiliation":[{"name":"School of Pharmacy, Massachusetts College of Pharmacy and Health Sciences, Boston"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Asabe E.","family":"Garba","sequence":"additional","affiliation":[{"name":"College for Public Health and Social Justice, Saint Louis University, St Louis, Missouri"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Quentin R.","family":"Regestein","sequence":"additional","affiliation":[{"name":"Department of Psychiatry, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tewodros","family":"Eguale","sequence":"additional","affiliation":[{"name":"School of Pharmacy, Massachusetts College of Pharmacy and Health Sciences, Boston"},{"name":"Division of General Internal Medicine, Brigham and Women's Hospital, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","published-online":{"date-parts":[[2019,3,22]]},"reference":[{"key":"zoi190050r1","doi-asserted-by":"publisher","first-page":"73","DOI":"10.3389\/fneur.2012.00073","article-title":"Behavioral and psychological symptoms of dementia.","volume":"3","author":"Cerejeira","year":"2012","journal-title":"Front Neurol"},{"issue":"2","key":"zoi190050r2","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1016\/j.maturitas.2014.04.005","article-title":"Neuropsychiatric aspects of dementia.","volume":"79","author":"Ford","year":"2014","journal-title":"Maturitas"},{"issue":"3","key":"zoi190050r3","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1016\/j.jamda.2012.09.027","article-title":"The prevalence and course of neuropsychiatric symptoms in nursing home patients with dementia: a systematic review.","volume":"14","author":"Selb\u00e6k","year":"2013","journal-title":"J Am Med Dir Assoc"},{"issue":"2","key":"zoi190050r4","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1002\/gps.v29.2","article-title":"Vascular risk factors and neuropsychiatric symptoms in Alzheimer\u2019s disease: the Cache County Study.","volume":"29","author":"Steinberg","year":"2014","journal-title":"Int J Geriatr Psychiatry"},{"issue":"6","key":"zoi190050r5","doi-asserted-by":"publisher","first-page":"714","DOI":"10.1093\/geront\/33.6.714","article-title":"Factors determining the decision to institutionalize dementing individuals: a prospective study.","volume":"33","author":"Cohen","year":"1993","journal-title":"Gerontologist"},{"issue":"5","key":"zoi190050r6","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1177\/2040622316658463","article-title":"Antipsychotic use in dementia: a systematic review of benefits and risks from meta-analyses.","volume":"7","author":"Tampi","year":"2016","journal-title":"Ther Adv Chronic Dis"},{"issue":"1","key":"zoi190050r7","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1001\/jamainternmed.2015.6058","article-title":"Association of off-label drug use and adverse drug events in an adult population.","volume":"176","author":"Eguale","year":"2016","journal-title":"JAMA Intern Med"},{"issue":"5","key":"zoi190050r8","doi-asserted-by":"publisher","first-page":"543","DOI":"10.1176\/appi.ajp.2015.173501","article-title":"The American Psychiatric Association practice guideline on the use of antipsychotics to treat agitation or psychosis in patients with dementia.","volume":"173","author":"Reus","year":"2016","journal-title":"Am J Psychiatry"},{"issue":"10113","key":"zoi190050r9","doi-asserted-by":"publisher","first-page":"2673","DOI":"10.1016\/S0140-6736(17)31363-6","article-title":"Dementia prevention, intervention, and care.","volume":"390","author":"Livingston","year":"2017","journal-title":"Lancet"},{"issue":"3","key":"zoi190050r12","doi-asserted-by":"publisher","first-page":"170","DOI":"10.1177\/0706743716673321","article-title":"Antipsychotic use in dementia: is there a problem and are there solutions?","volume":"62","author":"Kirkham","year":"2017","journal-title":"Can J Psychiatry"},{"issue":"11","key":"zoi190050r13","doi-asserted-by":"publisher","first-page":"2227","DOI":"10.1111\/jgs.13702","article-title":"American Geriatrics Society 2015 updated Beers criteria for potentially inappropriate medication use in older adults.","volume":"63","author":"American Geriatrics Society 2015 Beers Criteria Update Expert Panel","year":"2015","journal-title":"J Am Geriatr Soc"},{"issue":"2","key":"zoi190050r14","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1093\/ageing\/afu145","article-title":"STOPP\/START criteria for potentially inappropriate prescribing in older people: version 2.","volume":"44","author":"O\u2019Mahony","year":"2015","journal-title":"Age Ageing"},{"issue":"9994","key":"zoi190050r15","doi-asserted-by":"publisher","first-page":"628","DOI":"10.1016\/S0140-6736(15)61478-7","article-title":"Network meta-analysis: a norm for comparative effectiveness?","volume":"386","author":"Higgins","year":"2015","journal-title":"Lancet"},{"issue":"4","key":"zoi190050r16","doi-asserted-by":"publisher","first-page":"W65-W94","DOI":"10.7326\/0003-4819-151-4-200908180-00136","article-title":"The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration.","volume":"151","author":"Liberati","year":"2009","journal-title":"Ann Intern Med"},{"issue":"11","key":"zoi190050r17","doi-asserted-by":"publisher","first-page":"777","DOI":"10.7326\/M14-2385","article-title":"The PRISMA extension statement for reporting of systematic reviews incorporating network meta-analyses of health care interventions: checklist and explanations.","volume":"162","author":"Hutton","year":"2015","journal-title":"Ann Intern Med"},{"issue":"12","key":"zoi190050r18","doi-asserted-by":"publisher","first-page":"2308","DOI":"10.1212\/WNL.44.12.2308","article-title":"The Neuropsychiatric Inventory: comprehensive assessment of psychopathology in dementia.","volume":"44","author":"Cummings","year":"1994","journal-title":"Neurology"},{"issue":"1","key":"zoi190050r19","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1097\/00019442-200002000-00010","article-title":"The use of the Neuropsychiatric Inventory in nursing home residents.: characterization and measurement.","volume":"8","author":"Wood","year":"2000","journal-title":"Am J Geriatr Psychiatry"},{"issue":"3","key":"zoi190050r20","doi-asserted-by":"publisher","first-page":"799","DOI":"10.2466\/pr0.1962.10.3.799","article-title":"The Brief Psychiatric Rating Scale.","volume":"10","author":"Overall","year":"1962","journal-title":"Psychol Rep"},{"issue":"8","key":"zoi190050r21","first-page":"309","article-title":"Conceptualization of agitation: results based on the Cohen-Mansfield Agitation Inventory and the Agitation Behavior mapping instrument.","volume":"8","author":"Cohen-Mansfield","year":"1996","journal-title":"Int Psychogeriatr"},{"key":"zoi190050r22","doi-asserted-by":"publisher","first-page":"d5928","DOI":"10.1136\/bmj.d5928","article-title":"The Cochrane Collaboration\u2019s tool for assessing risk of bias in randomised trials.","volume":"343","author":"Higgins","year":"2011","journal-title":"BMJ"},{"issue":"2","key":"zoi190050r23","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1002\/jrsm.1037","article-title":"Indirect and mixed-treatment comparison, network, or multiple-treatments meta-analysis: many names, many benefits, many concerns for the next generation evidence synthesis tool.","volume":"3","author":"Salanti","year":"2012","journal-title":"Res Synth Methods"},{"key":"zoi190050r24","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1186\/1741-7015-11-159","article-title":"Is network meta-analysis as valid as standard pairwise meta-analysis? it all depends on the distribution of effect modifiers.","volume":"11","author":"Jansen","year":"2013","journal-title":"BMC Med"},{"key":"zoi190050r25","doi-asserted-by":"publisher","first-page":"e2017047","DOI":"10.4178\/epih.e2017047","article-title":"Network meta-analysis: application and practice using Stata.","volume":"39","author":"Shim","year":"2017","journal-title":"Epidemiol Health"},{"key":"zoi190050r26","doi-asserted-by":"publisher","first-page":"j3932","DOI":"10.1136\/bmj.j3932","article-title":"Multivariate and network meta-analysis of multiple outcomes and multiple treatments: rationale, concepts, and examples.","volume":"358","author":"Riley","year":"2017","journal-title":"BMJ"},{"issue":"2","key":"zoi190050r28","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1016\/j.jclinepi.2010.03.016","article-title":"Graphical methods and numerical summaries for presenting results from multiple-treatment meta-analysis: an overview and tutorial.","volume":"64","author":"Salanti","year":"2011","journal-title":"J Clin Epidemiol"},{"issue":"2","key":"zoi190050r29","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1002\/jrsm.1045","article-title":"Consistency and inconsistency in network meta-analysis: model estimation using multivariate meta-regression.","volume":"3","author":"White","year":"2012","journal-title":"Res Synth Methods"},{"key":"zoi190050r30","doi-asserted-by":"publisher","first-page":"d549","DOI":"10.1136\/bmj.d549","article-title":"Interpretation of random effects meta-analyses.","volume":"342","author":"Riley","year":"2011","journal-title":"BMJ"},{"issue":"6","key":"zoi190050r31","doi-asserted-by":"publisher","first-page":"683","DOI":"10.1016\/S0895-4356(97)00049-8","article-title":"The results of direct and indirect treatment comparisons in meta-analysis of randomized controlled trials.","volume":"50","author":"Bucher","year":"1997","journal-title":"J Clin Epidemiol"},{"issue":"7-8","key":"zoi190050r32","doi-asserted-by":"publisher","first-page":"932","DOI":"10.1002\/sim.3767","article-title":"Checking consistency in mixed treatment comparison meta-analysis.","volume":"29","author":"Dias","year":"2010","journal-title":"Stat Med"},{"issue":"4","key":"zoi190050r33","doi-asserted-by":"publisher","first-page":"905","DOI":"10.1177\/1536867X1501500402","article-title":"Visualizing assumptions and results in network meta-analysis: the network graphs package.","volume":"15","author":"Chaimani","year":"2015","journal-title":"Stata J"},{"issue":"1","key":"zoi190050r34","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1002\/jrsm.1167","article-title":"Automated generation of node-splitting models for assessment of inconsistency in network meta-analysis.","volume":"7","author":"van Valkenhoef","year":"2016","journal-title":"Res Synth Methods"},{"issue":"1","key":"zoi190050r35","doi-asserted-by":"publisher","first-page":"943","DOI":"10.18549\/PharmPract.2017.01.943","article-title":"Network meta-analysis: a technique to gather evidence from direct and indirect comparisons.","volume":"15","author":"Tonin","year":"2017","journal-title":"Pharm Pract (Granada)"},{"key":"zoi190050r36","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1016\/j.jclinepi.2018.02.009","article-title":"Is providing uncertainty intervals in treatment ranking helpful in a network meta-analysis?","volume":"100","author":"Veroniki","year":"2018","journal-title":"J Clin Epidemiol"},{"issue":"2","key":"zoi190050r37","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1002\/jrsm.57","article-title":"Using network meta-analysis to evaluate the existence of small-study effects in a network of interventions.","volume":"3","author":"Chaimani","year":"2012","journal-title":"Res Synth Methods"},{"key":"zoi190050r38","doi-asserted-by":"publisher","first-page":"c3515","DOI":"10.1136\/bmj.c3515","article-title":"Small study effects in meta-analyses of osteoarthritis trials: meta-epidemiological study.","volume":"341","author":"N\u00fcesch","year":"2010","journal-title":"BMJ"},{"issue":"7496","key":"zoi190050r39","doi-asserted-by":"publisher","first-page":"874","DOI":"10.1136\/bmj.38369.459988.8F","article-title":"Quetiapine and rivastigmine and cognitive decline in Alzheimer\u2019s disease: randomised double blind placebo controlled trial.","volume":"330","author":"Ballard","year":"2005","journal-title":"BMJ"},{"issue":"2","key":"zoi190050r40","doi-asserted-by":"publisher","first-page":"134","DOI":"10.4088\/JCP.v64n0205","article-title":"A randomized placebo-controlled trial of risperidone for the treatment of aggression, agitation, and psychosis of dementia.","volume":"64","author":"Brodaty","year":"2003","journal-title":"J Clin Psychiatry"},{"issue":"5","key":"zoi190050r41","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1097\/01.jcp.0000178415.22309.8f","article-title":"Aripiprazole for the treatment of psychosis in patients with Alzheimer\u2019s disease: a randomized, placebo-controlled study.","volume":"25","author":"De Deyn","year":"2005","journal-title":"J Clin Psychopharmacol"},{"issue":"2","key":"zoi190050r42","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1002\/(ISSN)1099-1166","article-title":"Olanzapine versus placebo in the treatment of psychosis with or without associated behavioral disturbances in patients with Alzheimer\u2019s disease.","volume":"19","author":"De Deyn","year":"2004","journal-title":"Int J Geriatr Psychiatry"},{"issue":"5","key":"zoi190050r43","doi-asserted-by":"publisher","first-page":"946","DOI":"10.1212\/WNL.53.5.946","article-title":"A randomized trial of risperidone, placebo, and haloperidol for behavioral symptoms of dementia.","volume":"53","author":"De Deyn","year":"1999","journal-title":"Neurology"},{"issue":"8","key":"zoi190050r44","doi-asserted-by":"publisher","first-page":"722","DOI":"10.1097\/00019442-200508000-00012","article-title":"Comparison of olanzapine and risperidone in the treatment of psychosis and associated behavioral disturbances in patients with dementia.","volume":"13","author":"Deberdt","year":"2005","journal-title":"Am J Geriatr Psychiatry"},{"issue":"2","key":"zoi190050r45","doi-asserted-by":"publisher","first-page":"107","DOI":"10.4088\/JCP.v60n0207","article-title":"Comparison of risperidone and placebo for psychosis and behavioral disturbances associated with dementia: a randomized, double-blind trial.","volume":"60","author":"Katz","year":"1999","journal-title":"J Clin Psychiatry"},{"issue":"17","key":"zoi190050r46","doi-asserted-by":"publisher","first-page":"1356","DOI":"10.1212\/01.wnl.0000260060.60870.89","article-title":"Quetiapine for agitation or psychosis in patients with dementia and parkinsonism.","volume":"68","author":"Kurlan","year":"2007","journal-title":"Neurology"},{"issue":"4","key":"zoi190050r47","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1002\/(ISSN)1099-1166","article-title":"Quetiapine treatment for behavioural and psychological symptoms of dementia in Alzheimer\u2019s disease patients: a 6-week, double-blind, placebo-controlled study.","volume":"23","author":"Paleacu","year":"2008","journal-title":"Int J Geriatr Psychiatry"},{"issue":"6","key":"zoi190050r48","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1016\/j.eurpsy.2007.03.001","article-title":"Quetiapine versus risperidone in elderly patients with behavioural and psychological symptoms of dementia: efficacy, safety and cognitive function.","volume":"22","author":"Rainer","year":"2007","journal-title":"Eur Psychiatry"},{"issue":"15","key":"zoi190050r49","doi-asserted-by":"publisher","first-page":"1525","DOI":"10.1056\/NEJMoa061240","article-title":"Effectiveness of atypical antipsychotic drugs in patients with Alzheimer\u2019s disease.","volume":"355","author":"Schneider","year":"2006","journal-title":"N Engl J Med"},{"issue":"10","key":"zoi190050r50","doi-asserted-by":"publisher","first-page":"968","DOI":"10.1001\/archpsyc.57.10.968","article-title":"Olanzapine treatment of psychotic and behavioral symptoms in patients with Alzheimer disease in nursing care facilities: a double-blind, randomized, placebo-controlled trial.","volume":"57","author":"Street","year":"2000","journal-title":"Arch Gen Psychiatry"},{"issue":"7","key":"zoi190050r51","doi-asserted-by":"publisher","first-page":"537","DOI":"10.1097\/JGP.0b013e318165db77","article-title":"A randomized, double-blind, placebo-controlled study of aripiprazole for the treatment of psychosis in nursing home patients with Alzheimer disease.","volume":"16","author":"Streim","year":"2008","journal-title":"Am J Geriatr Psychiatry"},{"issue":"9","key":"zoi190050r52","doi-asserted-by":"publisher","first-page":"767","DOI":"10.1097\/01.JGP.0000196628.12010.35","article-title":"Quetiapine treatment of psychosis associated with dementia: a double-blind, randomized, placebo-controlled clinical trial.","volume":"14","author":"Tariot","year":"2006","journal-title":"Am J Geriatr Psychiatry"},{"issue":"1","key":"zoi190050r53","doi-asserted-by":"publisher","first-page":"81","DOI":"10.2174\/156720507779939805","article-title":"Quetiapine to treat agitation in dementia: a randomized, double-blind, placebo-controlled study.","volume":"4","author":"Zhong","year":"2007","journal-title":"Curr Alzheimer Res"},{"issue":"3","key":"zoi190050r54","doi-asserted-by":"publisher","first-page":"280","DOI":"10.1097\/01.JGP.0000194643.63245.8c","article-title":"Risperidone in the treatment of psychosis of Alzheimer disease: results from a prospective clinical trial.","volume":"14","author":"Mintzer","year":"2006","journal-title":"Am J Geriatr Psychiatry"},{"issue":"11","key":"zoi190050r55","doi-asserted-by":"publisher","first-page":"918","DOI":"10.1097\/JGP.0b013e3181557b47","article-title":"Aripiprazole for the treatment of psychoses in institutionalized patients with Alzheimer dementia: a multicenter, randomized, double-blind, placebo-controlled assessment of three fixed doses.","volume":"15","author":"Mintzer","year":"2007","journal-title":"Am J Geriatr Psychiatry"},{"issue":"3","key":"zoi190050r56","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1097\/01.JGP.0000200589.01396.6d","article-title":"Efficacy and adverse effects of atypical antipsychotics for dementia: meta-analysis of randomized, placebo-controlled trials.","volume":"14","author":"Schneider","year":"2006","journal-title":"Am J Geriatr Psychiatry"},{"issue":"1","key":"zoi190050r57","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1136\/jnnp-2014-308112","article-title":"Pharmacological treatment of neuropsychiatric symptoms in Alzheimer\u2019s disease: a systematic review and meta-analysis.","volume":"86","author":"Wang","year":"2015","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"12","key":"zoi190050r58","doi-asserted-by":"publisher","first-page":"1359","DOI":"10.1001\/jama.2011.1360","article-title":"Efficacy and comparative effectiveness of atypical antipsychotic medications for off-label uses in adults: a systematic review and meta-analysis.","volume":"306","author":"Maher","year":"2011","journal-title":"JAMA"},{"issue":"1","key":"zoi190050r59","first-page":"CD003476","article-title":"The effectiveness of atypical antipsychotics for the treatment of aggression and psychosis in Alzheimer\u2019s disease.","author":"Ballard","year":"2006","journal-title":"Cochrane Database Syst Rev"},{"issue":"15","key":"zoi190050r60","doi-asserted-by":"publisher","first-page":"1934","DOI":"10.1001\/jama.294.15.1934","article-title":"Risk of death with atypical antipsychotic drug treatment for dementia: meta-analysis of randomized placebo-controlled trials.","volume":"294","author":"Schneider","year":"2005","journal-title":"JAMA"},{"issue":"3","key":"zoi190050r61","doi-asserted-by":"publisher","first-page":"915","DOI":"10.3233\/JAD-140579","article-title":"The efficacy and safety of atypical antipsychotics for the treatment of dementia: a meta-analysis of randomized placebo-controlled trials.","volume":"42","author":"Ma","year":"2014","journal-title":"J Alzheimers Dis"},{"issue":"5","key":"zoi190050r62","first-page":"S1","article-title":"Summary of the comparative effectiveness review on off-label use of atypical antipsychotics.","volume":"18","author":"Maher","year":"2012","journal-title":"J Manag Care Pharm"},{"issue":"5","key":"zoi190050r63","first-page":"617","article-title":"Adverse effects of antipsychotic medications.","volume":"81","author":"Muench","year":"2010","journal-title":"Am Fam Physician"},{"issue":"5","key":"zoi190050r64","doi-asserted-by":"publisher","first-page":"438","DOI":"10.1001\/jamapsychiatry.2014.3018","article-title":"Antipsychotics, other psychotropics, and the risk of death in patients with dementia: number needed to harm.","volume":"72","author":"Maust","year":"2015","journal-title":"JAMA Psychiatry"},{"issue":"1","key":"zoi190050r65","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1097\/00131746-200701000-00003","article-title":"EPS profiles: the atypical antipsychotics are not all the same.","volume":"13","author":"Weiden","year":"2007","journal-title":"J Psychiatr Pract"},{"issue":"4","key":"zoi190050r66","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1002\/pnp.2017.21.issue-4","article-title":"Association between antipsychotics and adverse outcomes in dementia.","volume":"21","author":"Bangash","year":"2017","journal-title":"Prog Neurol Psychiatry"},{"issue":"10","key":"zoi190050r67","doi-asserted-by":"publisher","first-page":"676","DOI":"10.4140\/TCP.n.2010.676","article-title":"Quetiapine for sleep in patients with dementia.","volume":"25","author":"Dolder","year":"2010","journal-title":"Consult Pharm"},{"key":"zoi190050r68","doi-asserted-by":"publisher","first-page":"918","DOI":"10.12688\/f1000research","article-title":"Hypnotic drug risks of mortality, infection, depression, and cancer: but lack of benefit.","volume":"5","author":"Kripke","year":"2016","journal-title":"F1000Res"},{"issue":"2","key":"zoi190050r69","doi-asserted-by":"publisher","first-page":"e008119","DOI":"10.1136\/bmjopen-2015-008119","article-title":"Sleep duration and mortality in the elderly: a systematic review with meta-analysis.","volume":"6","author":"da Silva","year":"2016","journal-title":"BMJ Open"},{"issue":"9","key":"zoi190050r71","doi-asserted-by":"publisher","first-page":"1395","DOI":"10.1503\/cmaj.1040539","article-title":"Olanzapine (Zyprexa): increased incidence of cerebrovascular events in dementia trials.","volume":"170","author":"Wooltorton","year":"2004","journal-title":"CMAJ"},{"issue":"5","key":"zoi190050r72","doi-asserted-by":"publisher","first-page":"957","DOI":"10.1038\/sj.npp.1301492","article-title":"ACNP White Paper: update on use of antipsychotic drugs in elderly persons with dementia.","volume":"33","author":"Jeste","year":"2008","journal-title":"Neuropsychopharmacology"},{"issue":"3","key":"zoi190050r73","doi-asserted-by":"publisher","first-page":"450","DOI":"10.1001\/jamainternmed.2014.6930","article-title":"Falls and fractures with atypical antipsychotic medication use: a population-based cohort study.","volume":"175","author":"Fraser","year":"2015","journal-title":"JAMA Intern Med"},{"issue":"1","key":"zoi190050r74","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1097\/JCP.0b013e3182a6096e","article-title":"Use and safety of antipsychotics in behavioral disorders in elderly people with dementia.","volume":"34","author":"Gareri","year":"2014","journal-title":"J Clin Psychopharmacol"},{"key":"zoi190050r75","doi-asserted-by":"publisher","first-page":"h369","DOI":"10.1136\/bmj.h369","article-title":"Assessment and management of behavioral and psychological symptoms of dementia.","volume":"350","author":"Kales","year":"2015","journal-title":"BMJ"},{"key":"zoi190050r10","author":"Pani","year":"2014"},{"key":"zoi190050r27","author":"Cohen","year":"1977"},{"key":"zoi190050r70","volume-title":"Off-Label Use of Atypical Antipsychotics: An Update.","author":"Maglione","year":"2011"},{"key":"zoi190050r11","unstructured":"Health Canada. Atypical antipsychotic drugs and dementia\u2014advisories, warnings and recalls for health professionals. http:\/\/www.healthycanadians.gc.ca\/recall-alert-rappel-avis\/hc-sc\/2005\/14307a-eng.php?_ga=2.105767104.2124339537.1537357160-1248280751.1537357160. Published June 22, 2005. Accessed September 20, 2018."}],"container-title":["JAMA Network Open"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/\/jamanetworkopen\/article-pdf\/2\/3\/e190828\/17395057\/yunusa_2019_oi_190050.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,11,22]],"date-time":"2019-11-22T02:55:50Z","timestamp":1574391350000},"score":1,"resource":{"primary":{"URL":"http:\/\/jamanetworkopen.jamanetwork.com\/article.aspx?doi=10.1001\/jamanetworkopen.2019.0828"}},"subtitle":["A Network Meta-analysis"],"short-title":[],"issued":{"date-parts":[[2019,3,22]]},"references-count":75,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2019,3,1]]}},"URL":"https:\/\/doi.org\/10.1001\/jamanetworkopen.2019.0828","relation":{},"ISSN":["2574-3805"],"issn-type":[{"value":"2574-3805","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,3,22]]}}}